U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H19ClN4O5
Molecular Weight 454.863
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIVOZANIB

SMILES

COC1=CC2=C(C=C1OC)C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=N2

InChI

InChIKey=SPMVMDHWKHCIDT-UHFFFAOYSA-N
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)

HIDE SMILES / InChI
Molecular Formula C22H19ClN4O5
Molecular Weight 454.863
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:46:52 UTC 2023
Edited
by admin
on Sat Dec 16 15:46:52 UTC 2023
Record UNII
172030934T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIVOZANIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
KIL8951
Code English
KIL-8951
Code English
UREA, N-(2-CHLORO-4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(5-METHYL-3-ISOXAZOLYL)-
Systematic Name English
N-(2-CHLORO-4-((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-N'-(5-METHYLISOXAZOL-3-YL)UREA
Systematic Name English
Tivozanib [WHO-DD]
Common Name English
tivozanib [INN]
Common Name English
KRN-951
Code English
TIVOZANIB [USAN]
Common Name English
AV-951
Code English
Classification Tree Code System Code
WHO-ATC L01XE34
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
NCI_THESAURUS C93259
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
Code System Code Type Description
RXCUI
2534233
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
CAS
475108-18-0
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
SMS_ID
100000134791
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
DRUG BANK
DB11800
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
DRUG CENTRAL
5258
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
EPA CompTox
DTXSID20963865
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
PUBCHEM
9911830
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
USAN
ZZ-29A
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
NCI_THESAURUS
C85444
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
INN
9203
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
ChEMBL
CHEMBL1289494
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
EVMPD
SUB64411
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
WIKIPEDIA
TIVOZANIB
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
DAILYMED
172030934T
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
FDA UNII
172030934T
Created by admin on Sat Dec 16 15:46:53 UTC 2023 , Edited by admin on Sat Dec 16 15:46:53 UTC 2023
PRIMARY
Related Record Type Details
Structure of TIVOZANIB
EXCRETED UNCHANGED
FECAL
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
TARGET -> INHIBITOR
IC50
Structure of TIVOZANIB HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA
TARGET -> INHIBITOR
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Protein binding of tivozanib is ≥ 99%, primarily to albumin in vitro and is independent of concentration.
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
expressed in extrahepatic tissues such as the lung and intestine, it is unlikely that this isoform would be extensively involved in generating the metabolites observed following incubations with human liver microsomes.
Structure of TIVOZANIB HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of TIVOZANIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Structure of TIVOZANIB
blood-to-plasma ratio PHARMACOKINETIC
Structure of TIVOZANIB
Tmax PHARMACOKINETIC
Structure of TIVOZANIB
Biological Half-life PHARMACOKINETIC
Structure of TIVOZANIB
Females had a longer estimated T1/2 (129 hours) compared to males (110 hours).
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966